Common use of Section 365(n) of the Bankruptcy Code Clause in Contracts

Section 365(n) of the Bankruptcy Code. All licenses granted under this Jounce Lead Co-Co Agreement are deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as defined in Section 101 of such Code. Each Party, as licensee, may fully exercise all of its rights and elections under the Bankruptcy Code. The Parties further agree that, if a Party elects to retain its rights as a licensee under any Bankruptcy Code, such Party shall be entitled to a complete duplicate of, or complete access to any technology licensed to it hereunder and all embodiments of such technology. Such embodiments of the technology shall be delivered to the licensee Party not later than: (a) the commencement of bankruptcy proceedings against the licensor, upon written request, unless the licensor elects to perform its obligations under this Jounce Lead Co-Co Agreement, or (b) if not delivered under Section 6.1.5(a), upon the rejection of this Jounce Lead Co-Co Agreement by or on behalf of the licensor, upon written request. Any agreements supplemental hereto will be deemed to be “agreements supplementary to” this Jounce Lead Co-Co Agreement for purposes of Section 365(n) of the Bankruptcy Code.

Appears in 2 contracts

Samples: Master Research and Collaboration Agreement (Jounce Therapeutics, Inc.), Master Research and Collaboration Agreement (Jounce Therapeutics, Inc.)

AutoNDA by SimpleDocs

Section 365(n) of the Bankruptcy Code. All licenses granted under this Jounce Celgene Lead Co-Co Agreement are deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as defined in Section 101 of such Code. Each Party, as licensee, may fully exercise all of its rights and elections under the Bankruptcy Code. The Parties further agree that, if a Party elects to retain its rights as a licensee under any Bankruptcy Code, such Party shall be entitled to a complete duplicate of, or complete access to any technology licensed to it hereunder and all embodiments of such technology. Such embodiments of the technology shall be delivered to the licensee Party not later than: (a) the commencement of bankruptcy proceedings against the licensor, upon written request, unless the licensor elects to perform its obligations under this Jounce Celgene Lead Co-Co Agreement, or (b) if not delivered under Section 6.1.5(a), upon the rejection of this Jounce Celgene Lead Co-Co Agreement by or on behalf of the licensor, upon written request. Any agreements supplemental hereto will be deemed to be “agreements supplementary to” this Jounce Celgene Lead Co-Co Agreement for purposes of Section 365(n) of the Bankruptcy Code.

Appears in 2 contracts

Samples: Master Research and Collaboration Agreement (Jounce Therapeutics, Inc.), Master Research and Collaboration Agreement (Jounce Therapeutics, Inc.)

Section 365(n) of the Bankruptcy Code. All licenses granted under this Jounce Lead Co-Co PD-1 License Agreement are deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as defined in Section 101 of such Code. Each Party, as licensee, may fully exercise all of its rights and elections under the Bankruptcy Code. The Parties further agree that, if a Party elects to retain its rights as a licensee under any Bankruptcy Code, such Party shall be entitled to a complete duplicate of, or complete access to any technology licensed to it hereunder and all embodiments of such technology. Such embodiments of the technology shall be delivered to the licensee Party not later than: (a) the commencement of bankruptcy proceedings against the licensor, upon written request, unless the licensor elects to perform its obligations under this Jounce Lead Co-Co PD-1 License Agreement, or (b) if not delivered under Section 6.1.5(a6.1.6(a), upon the rejection of this Jounce Lead Co-Co PD-1 License Agreement by or on behalf of the licensor, upon written request. Any agreements supplemental hereto will be deemed to be “agreements supplementary to” this Jounce Lead Co-Co PD-1 License Agreement for purposes of Section 365(n) of the Bankruptcy Code.

Appears in 2 contracts

Samples: Master Research and Collaboration Agreement (Jounce Therapeutics, Inc.), Master Research and Collaboration Agreement (Jounce Therapeutics, Inc.)

Section 365(n) of the Bankruptcy Code. All licenses granted under this Jounce Lead Co-Co License Agreement are deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as defined in Section 101 of such Code. Each Party, as licensee, may fully exercise all of its rights and elections under the Bankruptcy Code. The Parties further agree that, if a Party elects to retain its rights as a licensee under any Bankruptcy Code, such Party shall be entitled to a complete duplicate of, or complete access to any technology licensed to it hereunder and all embodiments of such technology. Such embodiments of the technology shall be delivered to the licensee Party not later than: (a) the commencement of bankruptcy proceedings against the licensor, upon written request, unless the licensor elects to perform its obligations under this Jounce Lead Co-Co License Agreement, or (b) if not delivered under Section 6.1.5(a6.1.6(a), upon the rejection [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. of this Jounce Lead Co-Co License Agreement by or on behalf of the licensor, upon written request. Any agreements supplemental hereto will be deemed to be “agreements supplementary to” this Jounce Lead Co-Co License Agreement for purposes of Section 365(n) of the Bankruptcy Code.

Appears in 1 contract

Samples: License Agreement (Juno Therapeutics, Inc.)

Section 365(n) of the Bankruptcy Code. All licenses granted under this Jounce Lead Co-Co [***]SM Agreement are deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as defined in Section 101 of such Code. Each Party, as licensee, may fully exercise all of its rights and elections under the Bankruptcy Code. The Parties further agree that, if a Party elects to retain its rights as a licensee under any Bankruptcy Code, such Party shall be entitled to a complete duplicate of, or complete access to any technology licensed to it hereunder and all embodiments of such technology. Such embodiments of the technology shall be delivered to the licensee Party not later than: (a) the commencement of bankruptcy proceedings against the licensor, upon written request, unless the licensor elects to perform its obligations under this Jounce Lead Co-Co the [***]SM Agreement, or (b) if not delivered under Section 6.1.5(a7.1.6(a), upon the rejection of this Jounce Lead Co-Co [***]SM Agreement by or on behalf of the licensor, upon written request. Any agreements supplemental hereto will be deemed to be “agreements supplementary to” this Jounce Lead Co-Co [***]SM Agreement for purposes of Section 365(n) of the Bankruptcy Code.

Appears in 1 contract

Samples: License Agreement (OncoMed Pharmaceuticals Inc)

AutoNDA by SimpleDocs

Section 365(n) of the Bankruptcy Code. All licenses granted under this Jounce Lead Co-Co Agreement are deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as defined in Section 101 of such Code. Each Party, as licensee, may fully exercise all of its rights and elections under the Bankruptcy Code. The Parties further agree that, if a Party elects to retain its rights as a licensee under any Bankruptcy Code, such Party shall be entitled to a complete duplicate of, or complete access to any technology licensed to it hereunder and all embodiments of such technology. Such embodiments of the technology shall be delivered to the licensee Party not later than: (a) the commencement of bankruptcy proceedings against the licensor, upon written request, unless the licensor elects to perform its obligations under this Jounce Lead Co-Co Agreement, or (b) if not delivered under Section 6.1.5(a7.1.6(a), upon the rejection of this Jounce Lead Co-Co Agreement by or on behalf of the licensor, upon written request. Any agreements supplemental hereto will be deemed to be “agreements supplementary to” this Jounce Lead Co-Co Agreement for purposes of Section 365(n) of the Bankruptcy Code.

Appears in 1 contract

Samples: License Agreement (OncoMed Pharmaceuticals Inc)

Section 365(n) of the Bankruptcy Code. All licenses granted under this Jounce Juno Lead Co-Co Agreement are deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as defined in Section 101 of such Code. Each Party, as licensee, may fully exercise all of its rights and elections under the Bankruptcy Code. The Parties further agree that, if a Party elects to retain its rights as a licensee under any Bankruptcy Code, such Party shall be entitled to a complete duplicate of, or complete access to any technology licensed to it hereunder and all embodiments of such technology. Such embodiments of the technology shall be delivered to the licensee Party not later than: (a) the commencement of bankruptcy proceedings against the licensor, upon written request, unless the licensor elects to perform its obligations under this Jounce Juno Lead Co-Co Agreement, or (b) if not delivered under Section 6.1.5(a6.1.6(a), upon the rejection of this Jounce Juno Lead Co-Co Agreement by or on behalf of the licensor, upon written request. Any agreements supplemental hereto will be deemed to be “agreements supplementary to” this Jounce Juno Lead Co-Co Agreement for purposes of Section 365(n) of the Bankruptcy Code.

Appears in 1 contract

Samples: License Agreement (Juno Therapeutics, Inc.)

Section 365(n) of the Bankruptcy Code. All licenses granted under this Jounce Celgene Lead Co-Co Agreement are deemed to be, for purposes of Section 365(n) of the Bankruptcy Code, licenses of rights to “intellectual property” as defined in Section 101 91 of such Code. Each Party, as licensee, may fully exercise all of its rights and elections under the Bankruptcy Code. The Parties further agree that, if a Party elects to retain its rights as a licensee under any Bankruptcy Code, such Party shall be entitled to a complete duplicate of, or complete access to any technology licensed to it hereunder and all embodiments of such technology. Such embodiments of the technology shall be delivered to the licensee Party not later than: (a) the commencement of [***] Certain information in this document has been omitted and filed separately with the Securities and Exchange Commission. Confidential treatment has been requested with respect to the omitted portions. bankruptcy proceedings against the licensor, upon written request, unless the licensor elects to perform its obligations under this Jounce Celgene Lead Co-Co Agreement, or (b) if not delivered under Section 6.1.5(a6.1.6(a), upon the rejection of this Jounce Celgene Lead Co-Co Agreement by or on behalf of the licensor, upon written request. Any agreements supplemental hereto will be deemed to be “agreements supplementary to” this Jounce Celgene Lead Co-Co Agreement for purposes of Section 365(n) of the Bankruptcy Code.

Appears in 1 contract

Samples: License Agreement (Juno Therapeutics, Inc.)

Time is Money Join Law Insider Premium to draft better contracts faster.